Discover why ResMed is a top buy with strong fundamentals, robust cash flow, and dividend potential—ideal for recession-proof ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...

The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and ...

(MENAFN- GetNews) Air Voel, a trusted name in sleep and respiratory wellness across Canada, proudly announces the expansion of its product lineup with the latest ResMed BiPAP and CPAP machines, ...

Air Voel, one of Canada’s leading providers of CPAP machines, masks, and sleep-health solutions, today announced the launch of its Sleep Better 2026 Initiative, a nationwide program designed to raise ...

Let's see why these shares could be great long term picks for Aussie investors. The post 2 screaming buy ASX shares I'd hold ...

One of the unique parts of Gardner's approach is that he doesn't mind if a stock is considered overvalued. In fact, if a company checks all the boxes, the "overvalued" label is another sign that it's ...

DexCom reported revenues of $1.21 billion, up 21.6% year on year. This print exceeded analysts’ expectations by 2.5%. Overall, it was a strong quarter for the company with a solid beat of analysts’ ...

A pioneering study, led by PFL Healthcare in collaboration with the University of Sheffield, has demonstrated that ...

The Sleep Apnea Devices industry is set to grow from US$ 6.47 Billion in 2024 to an impressive US$ 12.23 Billion by 2033, at ...

Those with the sleep condition were more likely to develop Parkinson’s disease. But one treatment was found to help.